Janus Henderson Group
HLVX

Janus Henderson Group’s HilleVax HLVX Stock Holding History

Janus Henderson Group’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,115,644
Closed -$16.1M – 2541
2024
Q2 		$16.1M Buy
+1,115,644
New +$15.3M 0.01% 610

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Janus Henderson Group's HLVX Position: Q3 2024 in Review

Janus Henderson Group sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 1,115,644 shares — an estimated $16.1M sold.

Janus Henderson Group first reported a position in HLVX in Q2 2024 and held it in 1 quarter. The position peaked at $16.1M in Q2 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

  • Janus Henderson Group reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
  • Janus Henderson Group sold 1,115,644 HilleVax shares in Q3 2024, an estimated $16.1M.
  • Janus Henderson Group first reported a position in HilleVax in Q2 2024 and held it in 1 quarter.
  • Janus Henderson Group's HilleVax position peaked at $16.1M in Q2 2024.
  • 79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on Janus Henderson Group's 13F filing for Q3 2024, filed 14 Nov 2024.